Plus Therapeutics, Inc. (NASDAQ: PSTV) reported Q4 EPS of ($0.77), $0.62 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $220 thousand versus the consensus estimate of $1.48 million.

For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.